HIMS·Hims & Hers Health, Inc.

B of A Securities raised its price target for Hims & Hers Health to $37 while keeping a neutral rating, reflecting confidence in the company’s expanding direct‑to‑consumer product portfolio, and traders should watch the upcoming quarterly earnings for updated margin and international expansion guidance. The company’s push into international markets and integration of new digital health tools is expected to broaden recurring revenue streams, and this expansion could lift the company’s valuation in the next 1–10 trading days, so monitor subscriber growth metrics in the earnings release. Argus Research’s recent target hike to $38 was based on stronger revenue projections and improved margin expectations, suggesting that the market may price in a more aggressive product pipeline, and watch for any updates on cost‑control initiatives. The latest earnings forecast of a Q2 EPS of –$0.07 and revenue of $690.21 million, up 26.68% YoY, indicates profitability pressure remains, and traders should keep an eye on actual earnings versus guidance to gauge the company’s ability to meet expectations. FDA staff’s recent safety questions about HIMS’s peptide products could delay approvals and impact revenue, and the market reaction may be short‑term if the issue is resolved, so watch for formal FDA statements or company responses. Despite the peptide safety concerns, an analyst noted the issue may not be terminal, implying that long‑term upside could persist, and traders should watch for any new safety data or regulatory clarifications. The $400 million working‑capital facility from JPMorgan provides liquidity that could support future capital allocation and expansion of pharmacy services, and this financial flexibility may underpin the company’s growth strategy, so monitor how the facility is deployed in the next earnings cycle. The company’s daily patient volume of 10,000–15,000 and ambition to become the industry’s “gold standard” suggest a solid operational base, and this could translate into sustained subscriber growth, so watch for updates on patient acquisition metrics. With multiple analysts raising price targets and the company securing significant working‑capital, the near‑term market may see upward pressure, but regulatory uncertainty around peptides remains a key risk, so keep an eye on FDA guidance and earnings for confirmation of growth prospects.